J.P. Morgan Rates CVS Caremark As Overweight

According to J.P. Morgan, CVS Caremark CVS is rated Overweight. J.P. Morgan said that, as part of CVS Caremark Week, it discusses takeaways from its conference call yesterday with Larry Merlo, CEO of CVS Caremark. “While nothing materially incremental came out of the call, we found Mr. Merlo's perspectives insightful, in particular, his comments around the integrated offering, the FEP contract decision, industry pricing, and PBM streamlining initiatives.” CVS Caremark closed yesterday at $37.51.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsConsumer StaplesCVS Caremark CorporationDrug RetailJ.P. Morgan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!